CN101772308A - 益生菌和纤维在腹泻上的应用 - Google Patents
益生菌和纤维在腹泻上的应用 Download PDFInfo
- Publication number
- CN101772308A CN101772308A CN200880101552A CN200880101552A CN101772308A CN 101772308 A CN101772308 A CN 101772308A CN 200880101552 A CN200880101552 A CN 200880101552A CN 200880101552 A CN200880101552 A CN 200880101552A CN 101772308 A CN101772308 A CN 101772308A
- Authority
- CN
- China
- Prior art keywords
- composition
- lactobacillus rhamnosus
- application
- inulin
- diarrhoea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 59
- 239000000835 fiber Substances 0.000 title description 24
- 239000006041 probiotic Substances 0.000 title description 6
- 235000018291 probiotics Nutrition 0.000 title description 6
- 239000000203 mixture Substances 0.000 claims abstract description 108
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 60
- 229920001202 Inulin Polymers 0.000 claims abstract description 51
- 229940029339 inulin Drugs 0.000 claims abstract description 51
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 50
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 244000068988 Glycine max Species 0.000 claims description 51
- 235000010469 Glycine max Nutrition 0.000 claims description 51
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 24
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000011701 zinc Substances 0.000 claims description 14
- 229910052725 zinc Inorganic materials 0.000 claims description 14
- 235000019621 digestibility Nutrition 0.000 claims description 13
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 235000014633 carbohydrates Nutrition 0.000 claims description 12
- 229910052742 iron Inorganic materials 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 201000009840 acute diarrhea Diseases 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 235000004252 protein component Nutrition 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 150000004676 glycans Chemical class 0.000 abstract description 3
- 229920001282 polysaccharide Polymers 0.000 abstract description 3
- 239000005017 polysaccharide Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 24
- 239000007788 liquid Substances 0.000 description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 12
- 239000002689 soil Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 210000001842 enterocyte Anatomy 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000021125 infant nutrition Nutrition 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000001142 anti-diarrhea Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 239000011785 micronutrient Substances 0.000 description 4
- 235000013369 micronutrients Nutrition 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000018343 nutrient deficiency Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000370738 Chlorion Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000019637 Infantile Diarrhea Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 206010019332 Heat exhaustion Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000002344 fibroplastic effect Effects 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
Abstract
本发明涉及一种用于治疗腹泻的营养组合物,包括鼠李糖乳杆菌(Lactobacillus rhamnosus)、菊粉和大豆多糖。
Description
技术领域
本发明属于用于预防和/或治疗腹泻的、包括益生菌和纤维的婴儿营养品领域。
背景技术
腹泻是严重的公共健康问题,是营养不良的主要成因,在发展中国家小于5岁的儿童特别是婴儿中,全部死亡病例的四分之一与之相关。腹泻每年导致10亿多次的疾病发作,全球平均每个儿童发作3次,全球范围内导致近500万死亡。
对于急性腹泻特别是婴儿的急性腹泻,目前的建议是补充流体和电解质损失,同时提供营养支持。但是这种治疗方法并没有缩短腹泻的持续时间。可缩短腹泻持续时间的选择包括使用抗生素、抗动力药物(anti-motility)和抑制分泌药物。但这并不总是有效,并经常带来严重的副作用。一般的一致观点是,在治疗婴儿急性胃肠炎时没有必要使用药理剂。
益生菌(probiotics),特别是乳杆菌种类(lactobacillus species),己被用作腹泻的预防剂和促进腹泻治愈的治疗剂。
EP 0904784涉及一种用于预防和治疗胃肠道疾病的营养制剂,包括一种双岐杆菌(Bifidobacterium)、屎肠球菌(Enterococcus faecium)和一种乳杆菌菌株,并优选地包括益生元(prebiotics)化合物。该制剂可为食品添加剂、即用食品组合物、婴儿配方或者管喂食品(tubefeeding)的形式,任选地包括纤维。
WO 2006/046871涉及一种用于治疗和/或预防脓毒症、菌血症和/或内毒素血症的组合物,包括鼠李糖乳杆菌(L.rhamnosus)并任选地包括纤维。
US 6,241,983涉及一种用于促进胃肠健康的组合物,包括益生菌和食物纤维。优选的有益的人肠道微生物包括乳杆菌和双歧杆菌。
WO 2006/110406涉及一种组合物,包括一种益生菌组分和一种增甜剂组分。
WO 2005/039319涉及一种组合物,包括非消化性寡糖和短双歧杆菌(Bifidobacterium breve)的混合物。
WO 2006/091103涉及一种组合物,包括短双歧杆菌、两种非消化性寡糖以及任选的副干酪乳杆菌(Lactobacillus paracasei)。
发明内容
本发明人发现,包含鼠李糖乳杆菌(L.rhamnosus)以及菊粉(inulin)和大豆多糖(大豆PS)的组合物对缩短腹泻的持续时间具有有益效果,该效果至少与所报道的单独使用鼠李糖乳杆菌的效果相似,同时该组合物可以通过向结肠提供可发酵基质来恢复微生物群,修复由腹泻导致的粘膜萎缩,并弥补营养缺乏。鼠李糖乳杆菌以及菊粉和大豆PS两者的结合还带来如下优点:减轻婴儿腹泻,食品中活细菌的存活力增强导致保质期延长,所食入的细菌中以存活形式到达结肠的数目增加,刺激结肠中外源细菌和内源细菌的生长和植入并使这些细菌的代谢作用活化,以及沿着小肠和结肠发挥作用。
不溶性大豆多糖的存在有利地使水从液态粪便中分离出来。包括鼠李糖乳杆菌、菊粉和大豆多糖的组合的组合物可有利地集合了如下作用:缩短腹泻的作用(如刺激免疫系统的作用)、提高益生菌菌株的存活力、改善微生物群、抗病原作用、提高矿物保持、提高水分保持、促进肠壁修复和/或弥补营养缺乏。该作用超出了单个组分的作用。
具体实施方式
本发明涉及一种治疗和/或预防人受试者的腹泻、特别是急性腹泻的方法,所述方法包括将含有鼠李糖乳杆菌、菊粉和大豆多糖的组合物给予所述的人受试者。换句话说,本发明涉及一种含有鼠李糖乳杆菌、菊粉和大豆多糖的组合物在制备用于治疗和/或预防人受试者的腹泻的营养组合物中的应用。本发明还可表述为一种用于治疗和/或预防人受试者的腹泻、特别是急性腹泻的组合物,包括鼠李糖乳杆菌、菊粉和大豆多糖。
鼠李糖乳杆菌
本发明的组合物包括鼠李糖乳杆菌。在存在于人肠道中的乳杆菌菌种中,该菌种是最丰富的菌种之一,已经发现属于该菌种的菌株可有效预防和/或治疗腹泻,包括婴儿急性腹泻。据称,预防或治疗腹泻的机制包括刺激免疫系统的作用、改善微生物群和/或直接的抗病原作用。优选地,当与典型株鼠李糖乳杆菌ATCC 7469(Stackebrandt&Goebel,1994,Int.J.Syst.Bacteriol.44:846-849)相比时,本发明中的鼠李糖乳杆菌的16S rRNA序列具有至少95%、更优选至少97%、进一步优选至少99%的同一性。鼠李糖乳杆菌在小肠和结肠中发挥它的抗腹泻作用。优选使用鼠李糖乳杆菌而不使用双歧杆菌,这是因为双歧杆菌只在大肠中有活性,鼠李糖乳杆菌在小肠中也可发挥作用,而小肠是经常发生引起腹泻的感染的地方。所以,使用鼠李糖乳杆菌代替双歧杆菌具有在小肠中也能对抗腹泻的优点。在乳杆菌菌种中优选使用鼠李糖乳杆菌,这是因为属于该菌种的菌株在肠道中是最丰富的,是最强健的,在对抗腹泻时是最有效的。
优选的鼠李糖乳杆菌菌株是从母乳喂养的健康人类婴儿的粪便中分离的那些菌株。几种鼠李糖乳杆菌菌株可从乳酸细菌的生产商处购买,但是它们也可以直接从粪便中分离,然后经识别、鉴定和生产。在一个优选的实施方案中,所述组合物包括至少一种选自下述的鼠李糖乳杆菌:鼠李糖乳杆菌LCS-742(Morinaga)、鼠李糖乳杆菌LR-35(Chr.Hansen)、鼠李糖乳杆菌GG(Valio)、鼠李糖乳杆菌HN001(Howaru)、鼠李糖乳杆菌R1039、R0011、R0049(Lallemand)、鼠李糖乳杆菌LBA 12.5U、LR-32(Rhodia)、鼠李糖乳杆菌271 231(Probi AB)、鼠李糖乳杆菌KCl(DSM)、鼠李糖乳杆菌LMG P-22799。更优选地,所述鼠李糖乳杆菌为菌株乳杆菌GG(ATCC 53103)。更优选地,所述鼠李糖乳杆菌为菌株LMGP-22799。鼠李糖乳杆菌菌株LMG P-22799表现出良好的技术特性,即没有不想要的抗生素抗性、在胃肠道中的高存活力、对肠细胞的良好的粘附性以及较好地防止肠病原粘附在肠细胞上。
该组合物在每克干重中优选地含有102至1012菌落形成单位(cfu)的鼠李糖乳杆菌,优选104至1011,更优选105至1010,最优选105至5×109。在每100ml即用组合物中,该组合物优选地含有103至1013cfu鼠李糖乳杆菌,优选104至1012,更优选105至1011,最优选106至5×1010cfu。本发明的鼠李糖乳杆菌的剂量优选为每日给予102至1013、更优选给予105至1011、最优选给予107至5×1010cfu。
菊粉
本组合物包含菊粉。菊粉是一种可被人微生物群发酵的水溶性纤维。在本文中,菊粉被定义为一种非消化性寡糖,包括一条聚合度(DP)为2至250的β连接的果糖单元的链,90%以上的果糖单元由β(2→1)键连接。果糖链的末端可以有也可以没有葡萄糖单元。因而菊粉可以由GFn或Fn表示,其中G代表葡萄糖基单元,F代表果糖基单元,n为互相连接的果糖基单元的数目,n为2或者更多。优选地,本发明中所用的菊粉的平均DP值为7或者更多。平均DP值优选至少10、更优选至少20。适合的菊粉例如为可购得的Raftiline ST、RaftilineHP(Orafti)或者Frutafit(Sensus)。与平均DP值较小的菊粉相比,使用平均DP值超过7、更优选超过10、更加优选超过20的菊粉可降低肠道的渗透负担,从而防止了在患腹泻时特别不想要的有害的通便作用。
菊粉的存在选择性地刺激肠道细菌、特别是乳杆菌的生长和/或活性。这种刺激尤其是发生在结肠中。从而有利地降低了pH值,形成了有机酸,例如乳酸和短链脂肪酸(包括特别是丁酸),这些有机酸具有抗病原作用(包括引发腹泻的病原),并且作为肠上皮细胞的能源(从而修复肠壁),它们还有助于矿物保持,这在腹泻时是特别有利的。另外,菊粉可刺激肠道中的益生菌菌株鼠李糖乳杆菌的生长、存活和/或代谢活性。这不仅包括大肠,还有利地包括小肠。
本发明营养组合物在每g干重中优选含有至少0.5mg菊粉,优选至少1.5mg,更优选至少5mg,更加优选至少10mg。优选地,本发明组合物在每g干重中含有不超过0.5g菊粉,更优选不超过0.35g,更加优选不超过0.2g,最优选不超过0.1g。本发明营养组合物在每100ml液态组合物中优选含有至少5mg菊粉,优选至少15mg,更优选每100ml至少50mg,甚至更加优选至少100mg。优选地,本发明组合物在每100ml中含有不超过10g菊粉,更优选每100ml不超过5g,甚至更加优选每100ml不超过2g,最优选每100ml不超过1g。本发明中菊粉的优选给予剂量为每天0.1至10g,更优选0.2至5g,更优选0.5至3g。
大豆多糖
本发明组合物中含有大豆多糖。在本发明中,术语“大豆多糖(PS)”和“大豆纤维”可互换使用,定义为从大豆中分离的非淀粉性、主要是不溶性的多糖。当在本发明中提及大豆多糖时,多糖被定义为DP值超过10、更优选超过20、更优选超过50、甚至更加优选超过100的糖。大豆纤维的适当来源有Fibrim(Solae)。大豆多糖中含有纤维素性和非纤维素性食物纤维。适用于本发明的通常市售来源的大豆多糖含有72-78%的总食物纤维(基于官方的AOAC法),该纤维组分由约94-95%的水不溶性纤维(纤维素和半纤维素)和约5-6%的水溶性纤维(如阿拉伯半乳聚糖之类的多糖)组成。
不溶性大豆多糖的存在有利地使水从液态粪便中分离出来。另外,大豆PS的存在有利地导致了丁酸的形成。丁酸是肠上皮细胞的能源,有助于修复由对抗致腹泻病原的炎症反应所引发的肠损伤。
本发明营养组合物在每g干重中优选含有至少0.8mg大豆PS,优选至少2.5mg,更优选至少8mg,甚至更加优选至少15mg。优选地,本发明组合物在每g干重中含有不超过0.8g大豆PS,更优选不超过0.6g,甚至更加优选不超过0.35g,最优选每g干重不超过0.15g。本发明营养组合物在每100ml液态组合物中优选含有至少8mg大豆PS,优选至少25mg,更优选每100ml至少80mg,甚至更加优选每100ml至少150mg。优选地,本发明组合物在每100ml中含有不超过15g大豆PS,更优选每100ml不超过8g,甚至更加优选每100ml不超过3g,最优选每100ml不超过1.5g。本发明中大豆PS的优选给予剂量为每日0.15至15g,更优选0.3至8g,更优选0.8至5g。
优选地,大豆PS与菊粉的重量比在5至0.2之间,更优选在3至0.5之间,甚至更加优选在2至1之间。菊粉与大豆PS之间有平衡的比例是有利的,这是因为这样可确保可溶性纤维与不溶性纤维之间的适当的比例,以及它们对于腹泻的不同的有益效果。为清楚起见,应该注意“大豆PS与菊粉的重量比在5至0.2之间”是指大豆PS的重量除以菊粉的重量等于一个介于5和0.2之间的数。
包括鼠李糖乳杆菌、菊粉和大豆多糖的组合的组合物可有利地集合如下作用:沿着整个肠道缩短腹泻的作用(如刺激免疫系统的作用)、提高益生菌菌株的存活力、改善微生物群、抗病原作用、提高矿物保持、提高水分保持、促进肠壁修复和/或弥补营养缺乏。该作用被认为超出了各单个组分的作用。特别是鼠李糖乳杆菌、大豆PS和菊粉的结合导致更多地形成了短链脂肪酸,包括丁酸和乳酸,以及在小肠中的作用增强。优选地,该组合物在每克大豆PS加菊粉中含有104至1012菌落形成单位(cfu)鼠李糖乳杆菌,优选106至1011,更优选107至1010,最优选108至5×109cfu。
微量营养素
本发明的组合物优选地含有锌。在发展中国家,儿童缺锌现象非常普遍。在腹泻时补充锌可缩短该治疗的疾病发作的持续时间和严重程度。在腹泻期间通常会过量产生一氧化氮(NO),作为自由基,一氧化氮可诱导分泌作用和细胞损伤。添加锌有助于改善小肠的生理状态,并有可能减少腹泻复发的风险。优选地,该组合物在每g干重中含有至少35μg锌,更优选至少60μg。优选地,该组合物在每g干重中含有不超过250μg锌。
本发明组合物优选地含有铁用以补充铁损失。并且,铁可缩短腹泻的持续时间。优选地,该组合物在每g干重中含有至少40μg,更优选至少80μg。优选地,该组合物在每g干重中含有不超过250μg铁。
优选地,该组合物同时含有锌和铁,这是因为发现同时补充锌和铁可减少患严重腹泻的风险。优选地,铁与锌的重量比在0.8和1.3之间。锌与铁有平衡的比例可确保锌和铁被适当地吸收。
营养组合物
本发明的组合物特别适于满足36个月以下的婴儿、特别是24个月以下的婴儿、更加优选12个月以下的婴儿的每日营养需求。因此,本发明的组合物优选地含有脂质组分、蛋白质组分和可消化性碳水化合物组分,其中脂质组分提供20至55%的总卡路里,所述蛋白质组分提供5至15%的总卡路里,所述可消化性碳水化合物组分提供30至75%的总卡路里。优选地,本发明组合物包括提供25至50%的总卡路里的脂质组分,提供6至13%的总卡路里的蛋白质组分,以及提供40至65%的总卡路里的可消化性碳水化合物组分。
当为液态形式,如即用型液态形式时,该组合物优选地每100ml含有1.0至6.5g脂肪,更优选每100ml含有1.8至4.0g。以干重计,本发明组合物优选地含有8至40wt.%脂肪,更优选12至30wt.%。在总脂肪酸中,饱和脂肪酸的量优选少于58wt.%,更优选少于45wt.%。基于总脂肪酸的重量,单不饱和脂肪酸的浓度优选在17至60%的范围。基于总脂肪酸的重量,多不饱和脂肪酸的浓度优选在20至60%的范围。优选地,该组合物含有n-6多不饱和脂肪酸亚油酸(LA)和n-3多不饱和脂肪酸α-亚麻酸(ALA)。LA/ALA重量比优选在4和10之间,更优选在5和7之间。
优选地,该组合物含有长链多不饱和脂肪酸,例如花生四烯酸、二十二碳六烯酸和/或二十碳五烯酸。优选存在n-3LC-PUFA,如EPA和/或DHA。n3-LC-PUFA可减轻肠的炎症反应,这对于患腹泻的婴儿来说是特别有利的。
当为液态形式,如即用型液态形式时,该组合物每100ml优选含有0.5至4g蛋白质,更优选每100ml含有1.0至3.0g。以干重计,本发明组合物优选含有5至30wt.%蛋白质,更优选10至20wt.%。以总蛋白质计,本发明组合物优选含有至少50wt.%的非人乳来源的蛋白质,更优选至少90wt.%。以总蛋白质计,本发明组合物优选含有至少50wt.%牛乳来源的蛋白质,更优选至少90wt.%。本发明组合物优选含有酪蛋白和/或乳清蛋白。酪蛋白与乳清蛋白的重量比优选为0∶100至100∶0,更优选10∶90至90∶10,更优选20∶80至80∶20。本发明中所用的术语“蛋白质”是指蛋白质、肽和游离氨基酸的总和。该组合物可任选地含有水解的蛋白质和/或游离氨基酸。优选地,该组合物不含有水解的蛋白质和/或游离氨基酸,因为这可增大该组合物的渗透负荷,对患有腹泻的人受试者来说是不利的。
当为液态形式,如即用型液态形式时,该组合物每100ml优选含有2至30g可消化性碳水化合物,更优选每100ml含有5至15g。以干重计,本发明组合物优选含有40至80wt.%可消化性碳水化合物,更优选50至70wt.%。该组合物优选含有至少一种选自下述的可消化性碳水化合物:乳糖、麦芽糊精、淀粉、蔗糖、葡萄糖和麦芽糖。优选地,本发明组合物含有麦芽糊精和/或淀粉。使用具有较高聚合度的可消化性碳水化合物来代替单糖和二糖可减轻渗透负荷,对患有腹泻的人受试者来说这是有利的。
本发明组合物优选含有稻米淀粉。与基于葡萄糖的口服补液(ORS)相比,已经发现基于稻米的口服补液可以更加有效地在患有急性传染性腹泻的儿童中减少粪便排出,缩短腹泻持续时间,以及促进液体和电解质的肠吸收。基于稻米的ORS的益处以前归因于其较低的渗透负荷、较快的吸收速度以及较高的碳水化合物含量。对于基于稻米的ORS可减少粪便排出以及促进吸收的另一种解释是稻米能够抑制肠分泌。
本发明组合物优选含有果胶(pectin)或果胶降解产物。果胶和/或其降解产物可有利地抑制引起腹泻的病原微生物粘附在肠壁上,从而减轻腹泻。
该组合物优选含有半乳寡糖(GOS),更优选β-连接的GOS。这些β-连接的GOS有益地减少引起腹泻的细菌与肠细胞之间的粘附。该组合物在每g干重中优选含有10至200mg β-连接的GOS,更优选20至90mg。β-连接的GOS的一个适当的来源是Vivinal(Borculo)。
该组合物优选含有核苷酸。可食用的核苷酸可有利地促进修复由导致腹泻的病原损害的肠细胞。
本发明组合物优选以液态形式给予。为满足婴儿的热量需求,该组合物优选含有50至200kcal/100ml液体,更优选60至90kcal/100ml液体,甚至更加优选60至75kcal/100ml液体。该热量密度可确保水和热量消耗之间的最佳比例。本发明组合物的渗透压优选在150和420mOsmol/l之间,更优选260至320mOsmol/l。该渗透压对于患腹泻的婴儿来说非常重要,有助于减轻胃肠压力,缓解腹泻。
优选地,该组合物为液态形式,其以Brookfield粘度计在20℃、100s-1的切变率测得的粘度值低于35cps。适当地,该组合物为粉末形式,可以用水重构形成液体,或者为液体浓缩形式,应该用水稀释。当该组合物为液体形式时,优选每天给予的体积在约80至2500ml的范围,更优选每天约450至1000ml。该组合物可用水适当地重构以形成半流体、可用匙舀起的组合物。
在一个优选的实施方案中,该组合物为包括鼠李糖乳杆菌、菊粉、大豆PS、葡萄糖以及钠、钾、氯离子的补液,且渗透压在200和320mOsmol/l之间,更优选在230和285mOsmol/l之间,最优选在235和245mOsmol/l之间。
应用
已发现根据本发明的组合物特别适合用作婴儿营养品,特别是早产婴儿、足月婴儿以及处于开始食用固体食物的断奶期的婴儿。因此,本发明提供了一种向人类婴儿提供营养的方法,所述方法包括将本发明组合物给予所述婴儿。优选地,所述婴儿的年龄介于0和36个月之间,更加优选0和18个月之间,最优选0和12个月之间。本发明组合物可有利地用于制备预防和/或治疗腹泻、特别是传染性腹泻、更特别是轮状病毒腹泻的药物。优选地,所述的含有鼠李糖乳杆菌、菊粉和大豆PS的组合物用于治疗急性腹泻。
在一个优选的实施方案中,鼠李糖乳杆菌、菊粉和大豆PS的组合物存在于还包括葡萄糖和电解质的口服补液中,在第一补液步骤中恢复水和电解质平衡,同时立即使鼠李糖乳杆菌、菊粉和大豆PS出现在胃肠道中。
优选地,在使用葡萄糖-电解质混合物进行约3至4小时的第一补液步骤以恢复水和电解质平衡之后再使用本发明组合物。鼠李糖乳杆菌、菊粉、大豆PS的组合物与脂质组分、可消化性碳水化合物组分和蛋白质组分一起,可快速恢复正常的粪便排出量和稠度,同时为特别是小肠壁提供生长和修复的营养。本发明组合物优选使用2-10天,更优选使用2-5天,直到腹泻痊愈。
在本说明书以及权利要求书中,动词“包括”及其变化形式以非限制性意义使用,指该词后面的项目被包括,但是没有具体提及的项目并不被排除。另外,用词语“一”或者“一个”修饰的要素并不排除该要素有多于一个的可能性,除非上下文明确要求有且只有一个该要素。因此,词语“一”或者“一个”一般指“至少一个”。
实施例
实施例1:使用鼠李糖乳杆菌、菊粉和大豆多糖的混合物以及微量
营养素的补充营养来缩短急性婴儿腹泻的持续时间
方法:
进行了随机、双盲临床试验以评价含有鼠李糖乳杆菌(益生菌)和食物纤维(菊粉和大豆多糖)的婴儿制剂在治疗58名患中度脱水急性腹泻的3-12个月的营养良好的印度尼西亚男婴时的效果。在足够地口服补液之后,患者被随机地分配接受:低乳糖婴儿制剂,包括鼠李糖乳杆菌(5×108/100ml)和食物纤维(0.15g菊粉/100ml和0.25g大豆多糖/100ml)的组合物以及较高浓度的几种特定的微量营养素(1.1mg铁/100ml、0.9mg锌/100ml、0.05mg铜/100ml、7μg锰/100ml、1.0μg硒/100ml、1.9mg维生素D3/100ml和1.1μg维生素E/100ml)(实验组);或者不含鼠李糖乳杆菌或食物纤维的低乳糖婴儿制剂(对照组),该制剂中含有标准浓度的微量营养素(0.5mg铁/100ml、0.5mg锌/100ml、0.04mg铜/100ml、1.4mg维生素D3/100ml和0.8μg维生素E/100ml)(对照组)。记录每个婴儿每天的下列数据:排便体积、排便频度和稠度以及精确的体重值。腹泻的持续时间被定义为入院后直到排出最后一次液态或半液态粪便(之后在24小时内没有再一次出现异常粪便)所经过的小时数。
结果:
两组患者在入院时在年龄、人体测量指标和营养状态、临床特征、治疗历史以及可能与腹泻发病率相关的实验室值等方面都是相当的。实验组的平均(SD)年龄为8.1(2.6)个月,对照组为8.0(2.7)个月。入院时,患者为中度脱水状态。在分离病原时,实验组和对照组之间没有检测到差异。在76%的病例中,轮状病毒是最主要的致病因素,这在实验组和对照组中是相同的。
与对照组相比,实验组的腹泻的持续时间显著缩短(实验组和对照组分别为1.63和2.45天;p<0.05),这在第一天的治疗后就变得很明显。该研究提供证据表明,在发展中国家,在口服补液之后提供含有益生菌、益生元和微量营养素的抗腹泻制剂具有缩短婴儿腹泻的持续时间的有益效果。与对照组相比,实验组更倾向于较低的粪便重量。在医院进行补液后,在第一天和第二天,实验组与对照组相比经食物治疗后倾向于具有较低的粪便排出量(以每千克体重每天的克数计)。
实施例2:大豆PS、菊粉和鼠李糖乳杆菌的协同作用
材料:
使用体外半动态批量发酵系统(semi-dynamic batch fermentationsystem),使用儿童粪便。
使用Fibrim(Solae公司)作为大豆PS来源。使用RaftilinST(Orafti)作为菊粉来源,使用L GG(Valio)作为鼠李糖乳杆菌来源。
从2岁的健康儿童获取新鲜粪便。
实验介质为McBain&MacFarlane介质(缓冲胨水3.0g/l、酵母提取物2.5g/l、胰蛋白胨3.0g/l、L-半胱氨酸-HCl 0.4g/l、胆盐0.05g/l、K2HPO4·3H2O 2.6g/l、NaHCO3 0.2g/l、NaCl 4.5g/l、MgSO4·7H2O 0.5g/l、CaCl2 0.228g/l、FeSO4 0.005g/l)。
方法:
将新鲜粪便材料与代表肠内环境的McBain&MacFarlane介质混合,重量比为1∶5。
在t=0时,将6ml粪便悬液与纤维和域L GG混合,转移至100ml瓶中的透析管中,所述瓶中装满缓冲透析介质(K2HPO4·3H2O 2.6g/l、NaHCO3 0.2g/l、NaCl 4.5g/l、MgSO4·7H2O 0.5g/l、CaCl2 0.228g/l、FeSO4·7H2O 0.005g/l,pH 6.3)。将该瓶盖好并在37℃温育。纤维和L GG的混合物如下所示:
48小时后用皮下注射器从透析管和透析缓冲液取0.5ml样品,在-18℃保存。实验平行做两份,所有操作均在无氧箱中进行。
乳酸的检测通过酶法使用带有D-和L-乳酸脱氢酶的乳酸检测试剂盒(Raisio Diagnostics Spa,Rome,Italy)进行。短链脂肪酸(SCFA)使用气相色谱检测,SCFA在MilliQ中提取。将2-乙基-丁酸用作内部标准。将样品在带有FID检测器的毛细管柱(Restek Stabilwax DA 15m×0.53×1.0μm;ZB-FFAB 15m×0.13×1.0μm)上分析。流动相为氦。
结果和结论:
结果以每g纤维形成的乳酸或SCFA的mmol量表示,示于表1中。
表1:不同纤维混合物发酵时形成的有机酸(mmol/g纤维)。
这些结果表明仅有鼠李糖乳杆菌时不会促进肠内发酵。大豆PS与菊粉相结合时与单独使用大豆PS相比,形成了更多的乳酸和SCFA。鼠李糖乳杆菌的存在进一步促进了大豆PS和菊粉混合物形成乳酸和SCFA。当单独使用菊粉时,观察到较多的乳酸和SCFA的形成。然而,几乎没有丁酸形成。在大豆PS或者大豆PS和鼠李糖乳杆菌的混合物中含有菊粉有利地促进了丁酸的形成。因此,大豆PS、菊粉和鼠李糖乳杆菌的混合物显示了对于患腹泻的儿童的最佳发酵特征。
实施例3:婴儿营养品
一种婴儿营养品,包括:
-植物脂肪组分,提供27%的总卡路里,多不饱和脂肪酸占总脂肪酸的40%,LA/ALA重量比为5.5。
-牛奶蛋白质组分,提供12%的总卡路里,由20wt.%的乳清蛋白和80wt.%的酪蛋白组成,以及
-可消化性碳水化合物组分,提供61%的总卡路里,包括超过80wt.%的麦芽糊精和淀粉。
-鼠李糖乳杆菌:5×108cfu/100ml。
-菊粉:0.15g/100ml
-大豆多糖:0.25/100ml
该婴儿营养品的包装的标签上标明该营养品在腹泻的情况下使用。
实施例4:
一种口服补液,每100ml包括:
2.0g葡萄糖、0.2g柠檬酸、138mg钠、78mg钾、177mg氯离子、1×108cfu鼠李糖乳杆菌、0.05g菊粉、0.10g大豆PS。
Claims (12)
1.一种包括鼠李糖乳杆菌(Lactobacillus rhamnosus)、菊粉和大豆多糖的组合物在制备用于治疗和/或预防人受试者腹泻的营养组合物中的应用。
2.根据权利要求1的应用,其中大豆PS∶菊粉的重量比在5至0.2之间。
3.根据前述权利要求中任一项的应用,其中所述组合物进一步包括可提供20至55%总卡路里的脂质组分、可提供5至15%总卡路里的蛋白质组分以及可提供30至75%总卡路里的可消化性碳水化合物组分。
4.根据前述权利要求中任一项的应用,其中所述的人受试者的年龄小于36个月。
5.根据前述权利要求中任一项的应用,其中所述组合物在每g干重组合物中含有104至1011cfu的鼠李糖乳杆菌。
6.根据前述权利要求中任一项的应用,其中所述鼠李糖乳杆菌为鼠李糖乳杆菌菌株LMG P-22799。
7.根据前述权利要求中任一项的应用,其中所述组合物在每g干重组合物中含有1.5至350mg的菊粉。
8.根据前述权利要求中任一项的应用,其中所述组合物在每g干重组合物中含有2.5至600mg的大豆多糖。
9.根据前述权利要求中任一项的应用,其中所述组合物在每g干重组合物中进一步含有至少35μg锌和/或40μg铁。
10.根据权利要求3-9中任一项的应用,其中所述的可消化性碳水化合物组分包括麦芽糊精和/或淀粉,并且其中所述的蛋白质组分包括非水解的蛋白质。
11.根据前述权利要求中任一项的应用,用于治疗急性腹泻。
12.根据前述权利要求中任一项的应用,用于治疗轮状病毒腹泻。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07111951.5 | 2007-07-06 | ||
EP07111951 | 2007-07-06 | ||
PCT/NL2008/050454 WO2009008717A1 (en) | 2007-07-06 | 2008-07-04 | Use of probiotics and fibers for diarrhoea |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101772308A true CN101772308A (zh) | 2010-07-07 |
CN101772308B CN101772308B (zh) | 2013-08-28 |
Family
ID=38522548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801015524A Active CN101772308B (zh) | 2007-07-06 | 2008-07-04 | 益生菌和纤维在腹泻上的应用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110014167A1 (zh) |
EP (1) | EP2173196B1 (zh) |
CN (1) | CN101772308B (zh) |
AT (1) | ATE498325T1 (zh) |
DE (1) | DE602008005025D1 (zh) |
ES (1) | ES2360573T3 (zh) |
PL (1) | PL2173196T3 (zh) |
PT (1) | PT2173196E (zh) |
RU (1) | RU2469558C2 (zh) |
WO (1) | WO2009008717A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
SG10201901259RA (en) | 2009-02-24 | 2019-03-28 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
WO2014062683A1 (en) * | 2012-10-15 | 2014-04-24 | University Of Florida Research Foundation, Inc. | Materials and methods for prevention and treatment of diarrhea and inflammation in the gastrointestinal tract |
ITMI20131467A1 (it) * | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
WO2015159125A1 (en) * | 2014-04-15 | 2015-10-22 | Compagnie Gervais Danone | Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after antibiotic dysbiosis |
MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
MA45327A (fr) | 2016-05-13 | 2019-03-20 | Sofar Spa | Utilisation de probiotiques pour améliorer l'absorption des protéines |
MA45288A (fr) | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
RU2767400C2 (ru) * | 2018-07-05 | 2022-03-17 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Пробиотическая композиция для восстановления и поддержания сбалансированной микрофлоры кишечника у детей и младенцев и способ ее получения |
JP7396798B2 (ja) * | 2019-02-22 | 2023-12-12 | 帝人株式会社 | 腸内酪酸産生促進用組成物 |
US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
EP4358983A1 (en) * | 2021-06-23 | 2024-05-01 | Danstar Ferment AG | Method for favoring wellness and facilitating self-control before, during and/or after a restrictive diet |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
EP1034787A1 (en) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
US20040185032A1 (en) * | 2003-03-18 | 2004-09-23 | David Burrell | Compositions and methods for treating colic |
JP4740866B2 (ja) * | 2003-10-24 | 2011-08-03 | ナムローゼ フェンノートシャップ ニュートリシア | 乳児向けシンバイオティック組成物 |
WO2006046871A2 (en) * | 2004-10-29 | 2006-05-04 | N.V. Nutricia | Peri-operative composition comprising lactobacillus rhamnosus |
WO2006091103A2 (en) * | 2005-02-28 | 2006-08-31 | N.V. Nutricia | Nutritional composition with probiotics |
US20100233312A9 (en) * | 2005-04-11 | 2010-09-16 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
EP1714660A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
WO2007098593A1 (en) * | 2006-03-03 | 2007-09-07 | Health Beverage, Llc | Fiber containing alkaline beverage and methods for production thereof |
-
2008
- 2008-07-04 PT PT08766875T patent/PT2173196E/pt unknown
- 2008-07-04 AT AT08766875T patent/ATE498325T1/de not_active IP Right Cessation
- 2008-07-04 PL PL08766875T patent/PL2173196T3/pl unknown
- 2008-07-04 US US12/667,898 patent/US20110014167A1/en not_active Abandoned
- 2008-07-04 DE DE602008005025T patent/DE602008005025D1/de active Active
- 2008-07-04 ES ES08766875T patent/ES2360573T3/es active Active
- 2008-07-04 WO PCT/NL2008/050454 patent/WO2009008717A1/en active Application Filing
- 2008-07-04 EP EP08766875A patent/EP2173196B1/en not_active Revoked
- 2008-07-04 RU RU2010104008/13A patent/RU2469558C2/ru not_active IP Right Cessation
- 2008-07-04 CN CN2008801015524A patent/CN101772308B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
WO2009008717A1 (en) | 2009-01-15 |
US20110014167A1 (en) | 2011-01-20 |
EP2173196A1 (en) | 2010-04-14 |
CN101772308B (zh) | 2013-08-28 |
ES2360573T3 (es) | 2011-06-07 |
ATE498325T1 (de) | 2011-03-15 |
DE602008005025D1 (de) | 2011-03-31 |
EP2173196B1 (en) | 2011-02-16 |
RU2010104008A (ru) | 2011-08-20 |
PT2173196E (pt) | 2011-05-23 |
RU2469558C2 (ru) | 2012-12-20 |
PL2173196T3 (pl) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101772308B (zh) | 益生菌和纤维在腹泻上的应用 | |
Zheng et al. | Current trends in marine algae polysaccharides: The digestive tract, microbial catabolism, and prebiotic potential | |
Tawfick et al. | Inulin fructans in diet: Role in gut homeostasis, immunity, health outcomes and potential therapeutics | |
JP6205003B2 (ja) | 腸内微生物叢バランス及び健康を促進するための栄養組成物 | |
Sánchez-Tapia et al. | Diet as regulator of gut microbiota and its role in health and disease | |
Di Bartolomeo et al. | Prebiotics to fight diseases: reality or fiction? | |
Bird et al. | Starches, resistant starches, the gut microflora and human health | |
Yan et al. | Prebiotics, FODMAPs and dietary fiber—conflicting concepts in development of functional food products? | |
Yasmin et al. | Prebiotics, gut microbiota and metabolic risks: Unveiling the relationship | |
JP5438003B2 (ja) | ラクトバチルスラムノサス及び体重管理 | |
JP5462191B2 (ja) | 中鎖ジカルボン酸、その誘導体及び代謝異常 | |
CN101938915A (zh) | 儿科的纤维混合物 | |
Bränning et al. | Blueberry husks and multi-strain probiotics affect colonic fermentation in rats | |
Sharma et al. | Prebiotics: A review of therapeutic potential | |
Zduńczyk | Physiological effect of low digestible oligosaccharides in diets for animals and humans. | |
JP2023518058A (ja) | ヒト対象でウロリチンの産生を増強するための組成物 | |
US20190307802A1 (en) | Probiotic compositions including immune modulators | |
Pandey et al. | Therapeutic applications of probiotic and prebiotic in metabolic syndrome and chronic kidney diseases | |
Mohammed et al. | Prebiotic and synbiotic effects of Lactobacillus rhamnosus isolated from Iraq on intestinal tract microflora in mice | |
US20070243272A1 (en) | Method for treating colon cancer with rice bran composition | |
US20220395542A1 (en) | Nutritional Compositions for Treating a Clostridium Difficile Infection | |
Biedrzycka | Microecosystem of the large intestine as a target-place for probiotics and prebiotics used as functional compounds of diet-a review. | |
Yañez-Sánchez et al. | Bio-functional activities of agavins on health | |
CN117615661A (zh) | 长双歧杆菌过渡型微生物的用途 | |
WO2023099750A1 (en) | Nutritional composition for improving infant microbiota |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |